Arca
Skip to content

IDH1: Isocitrate dehydrogenase [NADP] cytoplasmic

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Catalyzes the NADP(+)-dependent oxidative decarboxylation of isocitrate (D-threo-isocitrate) to 2-ketoglutarate (2-oxoglutarate), which is required by other enzymes such as the phytanoyl-CoA dioxygenase.

  • Drugs that act on it: 6
  • With a US drug page: 3
  • Type: Protein

Drugs That Act on It

Approved and clinical-stage drugs ChEMBL records for this target; those with a US drug page link to it. All act as: Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor.
IvosidenibApproved—InhibitorBoxed warning
OlutasidenibApproved—InhibitorBoxed warning
VorasidenibApproved—Inhibitor—
BAY1436032——Inhibitor—
IDH305——Inhibitor—
Safusidenib——Inhibitor—

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
Ollier disease
0.67
Glioma
0.64
Maffucci syndrome
0.63
Metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria
0.55
Low grade glioma
0.48
Glioma susceptibility 1
0.47
Acute myeloid leukemia by FAB classification
0.47

Genes and Related Targets

Complexes and families that share a gene with this target
Genes
IDH1
Related
IDH1/IDH2

Drugs and mechanisms are from ChEMBL CHEMBL2007625 (CC BY-SA 3.0). Gene name, function (UniProt O75874, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.